13 October 2023
13 October 2023
The dose-selection Phase I trials for evaluating PepGen’s peptide-conjugated antisense oligonucleotide have been cleared to begin in the US.
Care Access has been exonerated of wrongdoing at its clinical sites, but Pfizer and Valneva’s Phase III trial is now one year behind schedule.
Approximately 20% of the initial trial applications in the UK are expected to be eligible for faster approval.
In the mirikizumab arm, statistically higher proportion achieved clinical remission and endoscopic response at week 52.
The three-year data for Sotyktu indicates a consistent safety profile and strong efficacy.
British Columbia has announced a new regional clinical trials unit (CTU) to be based out of a Vancouver hospital priced at $4.2m.
The updated protocol intends to enhance the therapeutic window of sudocetaxel zendusortide and prolong the duration of treatment.
The Phase I clinical trial results are anticipated to be revealed in the latter part of next year.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
